New referral to the EBoA: post-filed experimental evidence and plausibility

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

New referral to the EBoA: post-filed experimental evidence and plausibility

Sponsored by

maiwald-logo-cropped.PNG
magnifip.png

Stefanie Parchmann of Maiwald considers the long-awaited referral to the Enlarged Board of Appeal regarding plausibility

At last – the long-awaited referral to the Enlarged Board of Appeal with respect to one of the most controversially discussed issues in European patent matters in recent times, i.e. plausibility, is here.

In the case, T 116/18, the Board of Appeal decided to refer three questions of law to the Enlarged Board of Appeal regarding plausibility and post-filed evidence (G 2/21).

The referral is made on the background of the long-standing practice of the Boards of Appeal that experimental evidence for the technical effect defined by applying the problem-solution approach may be submitted and taken into account to establish an inventive step, even though this evidence is not part of the application as filed. This practice was evolved in cases where the problem underlying the invention had to be reformulated as compared to the initial problem named in the application because of prior art found during examination or opposition proceedings.

In the wake of this practice, some boards requested that the said technical effect, even though it was formulated after the filing date of the application in question, and based on hitherto uncited prior art, nevertheless must at least be rendered plausible by the application as filed.

The Board in T 116/18 termed such technical effect rendered plausible by the application as filed as ‘ab-initio plausibility’. The Board of Appeal, however, also noted decisions in which this criterion for ab-initio plausibility was found to be incompatible with the problem solution approach because the applicant would be forced to cover a potentially extensive number of technical effects of an invention in the original application to ensure that these effects might later be taken into account when discussing inventive step.

The Board identified a further scenario it termed ‘ab-initio implausibility’. In this scenario, the question to be asked would be whether there were any reasons based on the common general knowledge to assume that the alleged technical effect was not obtained.

The Board also asked whether it was equitable to allow an opponent to rely on post-published evidence if the patentee was denied reliance on post-filed evidence to support plausibility?

The Board concluded that the following questions on plausibility and post-filed evidence required a referral to the Enlarged Board of Appeal (as summarised):

(1) Should post-filed data be disregarded if they are the sole evidence for a technical effect?

(2) Can post-filed data be taken into account if there is ab-initio plausibility?

(3) Can post-filed data be taken into account if there is ab-initio implausibility?

It remains to be seen whether the referral is admitted (already, there is a discussion breaking out whether the referral might be inadmissible because there is – contrary to the Board´s finding – neither a point of law of fundamental importance nor diverging case law to be decided upon) and, if so, which path the Enlarged Board of Appeal will cut through the thicket of opinions on plausibility.

 

Stefanie Parchmann

Partner, Maiwald

E: parchmann@maiwald.eu


more from across site and SHARED ros bottom lb

More from across our site

VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Patent attorney Michael Henson joins the firm to lead its freshly launched blockchain and digital assets practice
A dispute over mammogram technology, and a development in the case between GSK and Moderna were also among the top talking points in recent weeks
With rankings for Western Europe set to be published on June 25, we sat down with our research lead to find out what practitioners and law firms can expect
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Matteo Di Lernia, advocate at LCA Studio Legale, unpicks the CJEU’s ruling in M.M. Ristorazione v Villa Ramazzini, including its impact on litigation strategies
Gift this article